{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-121726","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2022-11-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.645607+00:00","generated_at":"2026-06-21T13:22:35.450888+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Esperion enters RIPA amendment with $50M partial call, waiver of defaults","bullets":["One-time partial call of $50M on Revenue Interests under amended Revenue Interest Purchase Agreement.","Cumulative Purchaser Payments reduced to $177,777,778.","Waived certain claimed defaults, breaches and Put Option Events related to new bank account.","Other material terms of RIPA and Security Agreement remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-121726","json":"https://secwatch.observer/filing/0001104659-22-121726.json","markdown":"https://secwatch.observer/filing/0001104659-22-121726.md","text":"https://secwatch.observer/filing/0001104659-22-121726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/0001104659-22-121726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/tm2231228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T13:22:35.450888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25d041c4ec971b7cabc953e11ca326a36f6e1c95","claim":"Esperion Therapeutics, Inc. amended Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement with the purchasers party thereto and Eiger III SA LLC valued at $50 million (effective 2022-11-23).","evidence_excerpt":"On November 23, 2022, Esperion Therapeutics, Inc. (the “Company”) entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the “RIPA Amendment”), by and among the Company, the purchasers party thereto (the “Purchasers”), and Eiger III SA LLC, as the collateral agent and administrative agent (the “Purchaser Agent”), which amends (i) the Revenue Interest Purchase Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465922121726/0001104659-22-121726-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"the purchasers party thereto and Eiger III SA LLC"},{"label":"Value","value":"$50 million"},{"label":"Effective","value":"2022-11-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}